These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25844263)

  • 21. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry.
    Pagano L; Caira M; Candoni A; Aversa F; Castagnola C; Caramatti C; Cattaneo C; Delia M; De Paolis MR; Di Blasi R; Di Caprio L; Fanci R; Garzia M; Martino B; Melillo L; Mitra ME; Nadali G; Nosari A; Picardi M; Potenza L; Salutari P; Trecarichi EM; Tumbarello M; Verga L; Vianelli N; Busca A;
    Clin Infect Dis; 2012 Dec; 55(11):1515-21. PubMed ID: 22955439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.
    Lundberg J; Höglund M; Björkholm M; Åkerborg Ö
    Clin Drug Investig; 2014 Jul; 34(7):483-9. PubMed ID: 24820968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.
    Döring M; Eikemeier M; Cabanillas Stanchi KM; Hartmann U; Ebinger M; Schwarze CP; Schulz A; Handgretinger R; Müller I
    Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1189-200. PubMed ID: 25680318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breakthrough invasive fungal infection in patients with myeloid malignancy receiving posaconazole tablet prophylaxis: Clinical features, risk factors, and posaconazole profiles.
    Hong JY; Kang CI; Yang J; Ko JH; Huh K; Cho SY; Chung DR; Jung CW; Peck KR
    Med Mycol; 2023 Apr; 61(5):. PubMed ID: 37120735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
    Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
    Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Single Center Experience for Antifungal Prophylaxis in Patients with Acute Myelogenous Leukemia.
    Metan G; Türe Z; Pala Ç; Kaynar L; Yıldırım A; Elmalı F; Tutar N; Yozgat N; Eser B
    Indian J Hematol Blood Transfus; 2015 Sep; 31(3):339-45. PubMed ID: 26085718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Posaconazole and fluconazole prophylaxis during induction therapy for pediatric acute lymphoblastic leukemia.
    Zhang T; Bai J; Huang M; Li R; Liu Y; Liu A; Liu J
    J Microbiol Immunol Infect; 2021 Dec; 54(6):1139-1146. PubMed ID: 32828790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Posaconazole : a review of its use in the prophylaxis of invasive fungal infections.
    Frampton JE; Scott LJ
    Drugs; 2008; 68(7):993-1016. PubMed ID: 18457464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study.
    Özkocaman V; Özkalemkaş F; Seyhan S; Ener B; Ursavaş A; Ersal T; Kazak E; Demirdöğen E; Mıstık R; Akalın H
    Turk J Haematol; 2018 Nov; 35(4):277-282. PubMed ID: 30047484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts.
    Lyseng-Williamson KA
    Pharmacoeconomics; 2011 Mar; 29(3):251-68. PubMed ID: 21309616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis.
    Calmettes C; Gabriel F; Blanchard E; Servant V; Bouchet S; Kabore N; Forcade E; Leroyer C; Bidet A; Latrabe V; Leguay T; Vigouroux S; Tabrizi R; Breilh D; Accoceberry I; de Lara MT; Pigneux A; Milpied N; Dumas PY
    Oncotarget; 2018 Jun; 9(42):26724-26736. PubMed ID: 29928481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States.
    Sung AH; Marcella SW; Xie Y
    J Med Econ; 2015 May; 18(5):341-8. PubMed ID: 25524741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia.
    Collins CD; Ellis JJ; Kaul DR
    Am J Health Syst Pharm; 2008 Dec; 65(23):2237-43. PubMed ID: 19020192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.
    Scott SA; Perry C; Mahmoudjafari Z; Martin GA; Boyd S; Thompson J; Thomas B
    Transpl Infect Dis; 2023 Apr; 25(2):e14045. PubMed ID: 36856447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis.
    Dranitsaris G; Khoury H
    Support Care Cancer; 2011 Nov; 19(11):1807-13. PubMed ID: 20972589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Breakthrough of invasive fungal disease with posaconazole as primary prophylaxis after induction chemotherapy for acute myeloid leukemia].
    Pei RZ; Lu Y; Zhang PS; Liu XH; Chen D; Du XH; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Tang SH
    Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):213-217. PubMed ID: 32146748
    [No Abstract]   [Full Text] [Related]  

  • 38. Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.
    Liebenstein TK; Widmer KM; Fallon MJ
    J Oncol Pharm Pract; 2018 Dec; 24(8):599-603. PubMed ID: 28768441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The latest data on posaconazole].
    Paugam A
    Med Mal Infect; 2007 Feb; 37(2):71-6. PubMed ID: 17267154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Prospective Study to Evaluate the Effect of Therapeutic Drug Monitoring-Based Posaconazole Prophylaxis on Invasive Fungal Infection Rate During Acute Myeloid Leukemia Induction Therapy.
    Boppana M; Sengar M; Jain H; Gurjar M; Ambotkar M; Gota V; Bonda A; Bagal B; Thorat J; Gokarn A; Nayak L; Shetty N; Baheti A; Mokal S; Kannan S; Shetty A; Eipe T
    Indian J Hematol Blood Transfus; 2024 Apr; 40(2):204-212. PubMed ID: 38708158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.